company background image

GeoVax Labs NasdaqCM:GOVX Stock Report

Last Price


Market Cap







06 Oct, 2022


Company Financials +
GOVX fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

GOVX Stock Overview

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform.

GeoVax Labs, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GeoVax Labs
Historical stock prices
Current Share PriceUS$1.12
52 Week HighUS$5.61
52 Week LowUS$0.55
1 Month Change1.82%
3 Month Change36.77%
1 Year Change-70.91%
3 Year Change-98.53%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Sep 08
We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

We Think GeoVax Labs (NASDAQ:GOVX) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Aug 08

GeoVax: Possible Vaccine Advancements In 2 Big Indications

GeoVax has multiple routes to go in terms of Covid-19 vaccine development; use of GEO-CM04S1 for Covid-19 in immunocompromised patients and as booster, plus GEO-CM02 as pan-coronavirus vaccine. GeoVax has the potential to possibly advance GEO-CM04S1 as a preventative Monkeypox vaccine. Successful prevention of Monkeypox in non-human primate models has been shown in peer-reviewed journal using MVA. Gedeptin is being developed for the treatment of patients with advanced head and neck cancer; MVA-VLP-MUC1 is also being advanced for the treatment of patients with solid tumors. GeoVax had $30.9 million in cash as of June 30, 2022; enough to fund its operations for at least the next 12 months. GeoVax Labs, Inc. (GOVX) is a great speculative biotech play to look into. That's because it only trades at $3 per share, but it has potential advancement for its vaccine technology in two key areas. These key areas are a Covid-19 vaccine which is ongoing in two phase 2 studies. One study is using GEO-CM04S1 as a Covid-19 vaccine and then another study using it as a booster. One key thing to note is that in terms of it being used as a Covid-19 vaccine, the phase 2 study is exploring it in immunocompromised cancer patients. This means that the biotech is specifically going after a subpopulation who may need stronger immunity against the virus. In addition, it has another shot on goal with a pan-corona virus vaccine it is working on, known as GEO-CM02. The other key area for which it is exploring the use of GEO-CM04S1 in is Monkeypox. That is, it is being explored as a prevention of Monkeypox. This vaccine technology of GEO-CM04S1 is what it is being used against other target indications such as HIV, Zika and Hemorrhagic fever viruses. The company is even expanding to cancer immunotherapy as well with its vaccine technology to develop additional shots on goal. It remains to be seen if the vaccine products ultimately work out, but I believe these two key indications could be huge value adding events. The other shots on goal in the pipeline are in early-stage testing but provide other opportunities. These are the reasons why I believe GeoVax is a great speculative biotech play to look into. Covid-19 Vaccine Possible For Patients Who Are Immunocompromised There are many Covid-19 vaccines out there and so the market is being overwhelmed with them. If that is the case, then how does GeoVax Labs hope to capitalize on advancing GEO-CM04S1 for Covid-19? There are three possibilities here. The first being that it is able to get this vaccine developed for those who are immunocompromised, especially those with cancer. The thing is that those who have cancer can't develop the antibodies necessary to fend off Covid-19. As such, they rely on T-cells only which is likely not enough. The point here is that there is an opportunity to target a specific sub-population of Covid-19 patients. This is how GeoVax can still capitalize on this market indication, without being overwhelmed. The use of GEO-CM04S1 is being explored in a phase 2 study as a primary vaccine for immunocompromised cancer patients. However, why I think this study is well powered is because it is being compared to a Pfizer (PFE)/BioNTech (BNTX) authorized messenger RNA ((mRNA)) vaccine named COMIRNATY. The primary endpoint of this phase 2 study is immune response over a 28 day period. Again, I think the opportunity here is to target-specific immunocompromised patients, especially those with cancer. The second opportunity lies in using GEO-CM04S1 as a vaccine booster in a phase 2 study. This vaccine is a synthetic modified vaccinia Ankara ((MVA))-based SARS-CoV-2 vaccine, for the prevention of Covid-19 infection. It was developed by GeoVax by putting in small pieces of SARS-CoV-2 DNA into synthetic MVA. The belief is that may be able to induce an immune response to recognize and kill off the virus. However, this study will compare the use of GEO-CM04S1 to placebo administration. The reason why I think this vaccine holds so much potential is because it's a dual approach. What do I mean by that? Well, all currently approved mRNA vaccines target the Spike protein in particular. On the other hand, GEO-CM04S1 targets two proteins. It targets both the Spike and nucleocapsid proteins. It remains to be seen if this dual targeting approach is much more adequate compared to only targeting the Spike protein alone, but there is huge potential for advancement here. Thus far, it has reported some pretty good data. For instance, back in March of 2022 is posted some results from a phase 1 study using GEO-CM04S1 in a peer-reviewed journal. The takeaway is that it was able to produce robust neutralizing antibodies and T cells against SARS-CoV-2 with no significant side effects. I think the huge promise here is that even if there eventually are additional mutations in the Spike protein, the company's dual targeting approach (targeting both Spike and nucleocapsid proteins) may still provide substantial immunity compared to those currently approved mRNA vaccines. This remains to be seen until the phase 2 results are posted, but this potential would be huge, especially for cancer patients who are really immunocompromised. The third opportunity lies with the use of GeoVax's pan-coronavirus vaccine, which is being developed as a universal vaccine for the virus. This is a good idea, because just in case the dual protein targeting approach doesn't pan out in phase 2 studies, it still has an opportunity to advance a single-dose vaccine. This single-dose vaccine being developed is known as GEO-CM02. The only problem with this program is that it is still in early development. Matter of fact, it is still being explored in preclinical studies. The purpose is to eventually get this pan-coronavirus vaccine ready for an IND filing and then subsequent human studies. Development Of A Vaccine For Monkeypox The thing is that GeoVax is doing pretty well in advancing its vaccine GEO-CM04S1 for Covid-19. However, it also has a great shot at developing a vaccine for Monkeypox as well. Why is that so? That's because the vaccine used and stockpiled for immunization against Monkeypox is MVA. As I noted above, modified vaccinia Ankara ((MVA)) is a vector also being used in all of GeoVax's vaccines targeting multiple indications such as HV, Zika, Hemorrhagic fever viruses and others. It is not quite yet a pandemic, but cases are starting to rise. As of this past Friday, there have been about 7,510 cases of Monkeypox in the United States. The majority of cases are coming from California, Florida, and New York. Globally, there has been more than 28,000 cases reported since January of this year. It's important to watch the spread of this, because it's possible that the spread could increase. There is a notion that it is not an STI and that it can be spread through close skin contact. Regardless, the rise in cases if anything should be monitored closely. Monkeypox DNA has been detected in feces and other bodily fluids. However, it is under investigation whether or not the mere presence of virus DNA found can cause a spread in these instances. The use of GeoVax's MVA-based HIV vaccine has shown to be successful in the prevention of Monkeypox in non-human primate models in a peer-reviewed publication. Preclinical studies are being done, and if the results are successful, then further studies could come about later on. The key thing is that this could open the scope for the GEO-CM04S1 MVA to be used for multiple indications. Even better, there is potential to prevent both hemorrhagic fever virus and the Monkeypox virus in a single vaccine. This has not yet been validated yet, but if it is in the coming months/year it would be a huge finding. Financials According to the 10-Q SEC Filing, GeoVax Labs Inc. had $30.9 million in cash as of June 30, 2022. The reason why it has so much cash on hand is because of a follow-on offering and private placement of common stock and warrants it had done in May of 2022. This was a registered direct and PIPE offering in which it was able to raise approximately $20 million. This is on top of the cash it had already raised back in January of 2022, which was $9.2 million. This financial transaction was a private placement of common stock and warrants. I believe that going forward the biotech will likely need to raise additional cash. It hopes to provides updates on its programs throughout 2022. If positive news is released in this 2nd half of 2022 (program/trial updates), then I expect it to raise cash immediately. Why I do believe this will be the case? That's because GeoVax notes in its 10-Q SEC filing that it believes it has enough cash to fund its operations for at least the next 12 months. It will not wait until the very end to raise cash. As such, it will likely take advantage of an immediate rise in stock price. However, such a rise will only occur if one of the ongoing studies have positive results reported. Risks To Business There are several risks that investors should be aware of before investing in GeoVax. The first risk being the Covid-1 vaccine program. That's because both the use of GEO-CM04S1 as a Covid-19 vaccine for the immunocompromised and as a booster are being evaluated in two ongoing phase 2 studies. There is no guarantee that either of these mid-stage studies will end up being successful. Even if they are successful, plus the company is able to obtain EUA for GEO-CMS04S1, there is no assurance that the vaccine will do well on the global stage. As I noted directly above in the beginning, there are many other regulatory approved vaccines, especially the most popular ones being Pfizer/BioNTech COMIRNATY and Moderna (MRNA) Spikevax. Pfizer believes that it could earn as much as $32 billion in revenue for COMIRNATY. Moderna did well for itself back in 2021, where it earned full year revenue of $18.5 billion. It already has in place the ability to earn $21 billion from Advance Purchase Agreements in 2022.

Jul 28

GeoVax adds 16% as journal publishes animal study on ebolavirus vaccine

The shares of clinical-stage biotech GeoVax Labs (NASDAQ:GOVX) added ~16% in the morning hours Thursday after the company announced a peer-reviewed publication of an animal efficacy study on the company’s experimental vaccine for Sudan ebolavirus (SUDV). According to data posted on the Nature Partner Journals (NPJ) Vaccines, a single dosed of the vaccine, MVA-VLP-SUDV, was found to generate 100% protection in the study involving guinea pigs. A second vaccine dose further bolstered the vaccine responses of the animals, the company said, adding that all animals which received either one or two doses of MVA-VLP-SUDV developed protection against death and symptoms following a lethal dose of SUDV. “The resulting immune responses are broadly functional, involving both the antibody and T-cell effector function, resulting in optimal levels of efficacy, even with a single dose,” Chief Executive of GeoVax (GOVX) Mark J. Newman explained. The company is close to completing its ongoing study for the candidate involving nonhuman primates. Benefitting from the recent monkeypox outbreak, GeoVax (GOVX) shares have climbed ~94% over the past 30 days, as shown in this graph.

Shareholder Returns

GOVXUS BiotechsUS Market

Return vs Industry: GOVX underperformed the US Biotechs industry which returned -19.3% over the past year.

Return vs Market: GOVX underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is GOVX's price volatile compared to industry and market?
GOVX volatility
GOVX Average Weekly Movement51.3%
Biotechs Industry Average Movement11.2%
Market Average Movement7.0%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: GOVX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 51% a week.

Volatility Over Time: GOVX's weekly volatility has increased from 33% to 51% over the past year.

About the Company

198811David Dodd

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S.

GeoVax Labs, Inc. Fundamentals Summary

How do GeoVax Labs's earnings and revenue compare to its market cap?
GOVX fundamental statistics
Market CapUS$27.71m
Earnings (TTM)-US$20.36m
Revenue (TTM)US$276.90k


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GOVX income statement (TTM)
Cost of RevenueUS$16.76m
Gross Profit-US$16.48m
Other ExpensesUS$3.88m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.82
Gross Margin-5,951.34%
Net Profit Margin-7,353.76%
Debt/Equity Ratio0.0%

How did GOVX perform over the long term?

See historical performance and comparison